Extended access to rufinamide for study completers
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial offers continued access to the study drug rufinamide for people who completed an earlier study in Poland. It aims to provide ongoing treatment while collecting more safety information.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in and completed the previous rufinamide study in Poland.
- You must have received rufinamide treatment during that study, not the other antiepileptic drug.
- You must be willing to continue receiving rufinamide through this extended access program.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program lets people who have already finished a clinical trial of the study drug LP352 and are still getting benefit from it keep receiving it. It's designed for those with developmental epileptic encephalopathy (a type of epilepsy that starts in childhood and affects development).
This program provides continued access to the investigational drug rugonersen for people with Angelman syndrome who were previously in the TANGELO study. The goal is to keep offering treatment that may help manage symptoms, while closely monitoring safety.
This trial provides continued access to lorcaserin, a study drug that may help reduce seizures in people with Dravet syndrome or other hard-to-treat epilepsies. It's for people who are already taking the drug and finding it helpful.
This study tests the long-term safety and effectiveness of RAP-219, an investigative medication for focal epilepsy. It is for people who already completed an earlier study of RAP-219, have a type of epilepsy that doesn't respond to standard medicines, and use a surgically implanted brain device (RNS system) to help manage seizures.
This trial is for people who are already in a RVU120 study and have been receiving the drug for at least 5 cycles. It allows you to keep getting RVU120 if you are benefiting from it and don't have other treatment options.
This trial is for people who finished a 12-week study (NCT06221852) and still meet its original requirements. It offers continued access to the study treatment.
Hear when a new Lennox Gastaut Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.